Clinical Trials Sponsored by IDRx, Inc.

Total 35491 results

IDRx, Inc.

Recruiting

A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST 1]

Gastrointestinal Diseases | Metastatic Cancer | Digestive System Disease | Gastrointestinal Stromal Tumor (GIST)

United States, Belgium, Germany, Spain
Quratis Inc.
IDRI

Unknown

Phase 2a Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Healthcare Workers

Tuberculosis

Korea, Republic of
IDRI

Completed

Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers

Leishmaniasis

United States
IDRI

Completed

A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis

Cutaneous Leishmaniasis

Peru
IDRI

Completed

Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDL

Post Kala Azar Dermal Leishmaniasis

Sudan
IDRI
Rockefeller University

Completed

The Effects of GLA (5 mcg) on Human Volunteers

Healthy Volunteers

United States
IDRI
American Leprosy Missions

Completed

Phase 1 LEP-F1 + GLA-SE Vaccine Trial in Healthy Adult Volunteers

Leprosy

United States
Curevo Inc
Green Cross Corporation; IDRI; Mogam Biotechnology Research Institute

Completed

Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects

Herpes Zoster | Varicella Zoster

United States
IDRI
Bill and Melinda Gates Foundation

Completed

Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite

Cutaneous Leishmaniasis

Colombia
IDRI
Bill and Melinda Gates Foundation

Completed

Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers

Visceral Leishmaniasis

United States
IDRI
Bill and Melinda Gates Foundation

Completed

Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India

Visceral Leishmaniasis | Post-kala-azar Dermal Leishmaniasis

India
Rockefeller University
Immune Design; IDRI Corporation

Completed

The Effects of GLA on Human Volunteers

Healthy Volunteers

United States
IDRI
Bill and Melinda Gates Foundation

Completed

Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis

Leishmaniasis, Mucocutaneous

Peru
IDRI
Bill and Melinda Gates Foundation

Completed

Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis

Leishmaniasis, Cutaneous

Brazil
IDRI
Bill and Melinda Gates Foundation

Completed

Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite

Cutaneous Leishmaniasis

Colombia
IDRI
South African Tuberculosis Vaccine Initiative; Aeras

Completed

Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers

Pulmonary Tuberculosis

South Africa
IDRI
Aeras; Paul G. Allen Family Foundation

Completed

Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers

Pulmonary Tuberculosis

United States
IDRI
Defense Advanced Research Projects Agency; Medicago

Completed

H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers

Influenza A Subtype H5N1 Infection

United States
IDRI
Wellcome Trust; South African Tuberculosis Vaccine Initiative

Completed

Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion

Pulmonary Tuberculosis

South Africa
International Centre for Diarrhoeal Disease Research...
IDRI; Nagasaki University

Completed

A Community Trial for Visceral Leishmaniasis (VL)

Visceral Leishmaniasis

Bangladesh
IND Diagnostic Inc.

Unknown

Evaluation of the IND One Step Strep A Rapid Test vs. Culture

Strep Throat

United States
Oswaldo Cruz Foundation
IDRI; Biomedical Research Center EPLS; Orygen Biotecnologia SA

Completed

Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children

Schistosomiasis

Senegal
Oswaldo Cruz Foundation
IDRI; Biomedical Research Center EPLS; Orygen Biotecnologia SA

Completed

Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions

Schistosomiasis

Senegal
Celularity Incorporated
Lung Biotechnology PBC; California Institute for Regenerative Medicine (CIRM); ID...

Active, not recruiting

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 (CYNKCOVID)

Coronaviridae Infections | Nidovirales Infections | RNA Virus Infections | Respiratory Tract Infections | Coronavirus Infection | Pneumonia, Viral | Pneumonia | Lung Diseases | ARDS | Coronavirus | Severe Acute Respiratory Syndrome Coronavirus 2 | Respiratory Tract Disease | Virus Disease | Physiological Effects of... and other conditions

United States
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.; Oncoceutics, Inc.

Recruiting

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Metastasis | Endometrial Cancer

United States
U.S. Army Medical Research and Development Command
United States Agency for International Development (USAID); IDRI

Completed

Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults

Malaria

United States
NC Medial Research Inc

Recruiting

A Study of NCS-01 in Patients With Acute Ischemic Stroke

Ischemic Stroke

United States
IC-IT Sciences Inc.

Unknown

Comparison of the Natural Frequencies Technology Sleep Patches to Sham Patches During Sleep in the Home Environment

Sleep Disturbance

United States
Zhengzhou Gensciences Inc
Haimen Gensciences lnc

Completed

An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

Hemophilia A

China
Zhengzhou Gensciences Inc
Jiangsu Gensciences lnc.

Completed

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A (RH-107-III02)

Hemophilia A

China
UNC Lineberger Comprehensive Cancer Center
Seagen Inc.

Completed

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

Hodgkin Lymphoma, Adult

United States
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.

Terminated

Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids (NRR)

Graft Versus Host Disease

United States
UNC Lineberger Comprehensive Cancer Center
Veracyte, Inc.

Recruiting

Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA (HARMONY)

Breast Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Seagen Inc.

Active, not recruiting

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

Lymphoma | Lymphatic Diseases | Adult T-Cell Leukemia/Lymphoma

United States
IGC Pharma LLC

Completed

Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease

Dementia of Alzheimer Type

Puerto Rico
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.

Completed

Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation

Hematologic Malignancies | Malignant Solid Tumor

United States
IGC Pharma LLC

Recruiting

IGC-AD1 Trial on Agitation in Dementia Due to Alzheimer's (IGC-AD1-P2)

Aggression | Depression | Anxiety | Alzheimer Disease | Memory Impairment | Agitated; State, Acute Reaction to Stress | Agitation,Psychomotor | Care Giving Burden | NPS | Aggressive Outburst

United States, Canada, Puerto Rico
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.

Recruiting

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

United States
Novan, Inc.
Synteract, Inc.; Therapeutics, Inc.

Completed

A Phase 3 Molluscum Contagiosum Efficacy and Safety Study (B-SIMPLE4)

Molluscum Contagiosum

United States
OBELAB, Inc.
Helptrial Inc.

Not yet recruiting

Evaluation of rSO2 Between Frontal Lesion Area and Normal Area of Brain by NIRSITX Using NIRS in Acute Ischemic Stroke Patients.

Acute Ischemic Stroke Patients

Korea, Republic of
Athersys, Inc
Medpace, Inc.

Recruiting

MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study (MASTERS-2)

Ischemic Stroke

United States, Taiwan
89bio, Inc.
ProSciento, Inc.

Completed

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

NASH

United States, Puerto Rico
ModernaTX, Inc.
Aetion, Inc.

Active, not recruiting

Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran

SARS-CoV-2

United States
Eisai Inc.
Quintiles, Inc.

Terminated

FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer

Colorectal Cancer

United States, Australia, Russian Federation, India, Ukraine
AxeroVision, Inc.
ORA, Inc.

Completed

A Study to Evaluate AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease

Dry Eye

United States
Versartis Inc.

Completed

Long-Acting Growth Hormone in Children Compared to Daily rhGH (VELOCITY)

Growth Disorders
Novan, Inc.
Synteract, Inc.

Completed

A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)

Molluscum Contagiosum

United States
EmitBio Inc.

Completed

Phase I/II Safety, Dose Finding & Antiviral Activity of RD-X19 in Mild/Moderate Outpatient COVID-19

COVID19

United States
Xoft, Inc.
Icad, Inc.

Withdrawn

An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite"

Ductal Carcinoma In Situ | Invasive Ductal Carcinoma
Versartis Inc.

Completed

Versartis Trial in Children to Assess Long-Acting Growth Hormone (VERTICAL)

Pediatric Growth Hormone Deficiency

United States

Clinical Trials Sponsored by IDRx, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations